title: [Usefulness of weekly administration of paclitaxel for advanced or recurrent gastric cancer].
abstract: We report herein the efficacy and feasibility of weekly administration of paclitaxel for advanced/recurrent gastric cancer retrospectively. Eleven patients with advanced or recurrent gastric cancer who had received prior chemotherapy were treated with this regimen. Seventy mg of paclitaxel per m2 dissolved in 250 ml 5% glucose was administered by 1-hour intravenous infusion once a week for 3 weeks followed by 1 week rest. To avoid hypersensitivity reactions, the following short premedication was given to all the patients 1 hour before paclitaxel treatment: Dexamethasone 20 mg intravenously (i.v.), diphenhydramine 50 mg i.v., and ranitidine 50 mg i.v. Treatment cycle was 1 to 23 with an average cycle of 5.4. The response rate was 33% (2/6 with measurable lesions), the median time to progression was 104 days, and the median survival time was 160 days. Grade 3 neutropenia occurred in 27.2% of the patients. Weekly paclitaxel may be a promising regimen as a second-line chemotherapy for advanced/recurrent gastric cancer. However, special attention needs to be paid to the neutropenic adverse effect in gastric cancer patients with poor performance status than 2 (greater).
authors.affiliation: Dept. of Surgery, Saiseikai Kanagawa-ken Hospital.
authors.forename: Tomohisa
authors.initials: T
authors.lastname: Egawa
authors.forename: Tetsuro
authors.initials: T
authors.lastname: Kubota
authors.forename: Atsushi
authors.initials: A
authors.lastname: Nagashima
authors.forename: Masakazu
authors.initials: M
authors.lastname: Doi
authors.forename: Mitsuhide
authors.initials: M
authors.lastname: Kitano
authors.forename: Shinobu
authors.initials: S
authors.lastname: Hayashi
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Yoshii
authors.forename: Yoshiro
authors.initials: Y
authors.lastname: Saikawa
authors.forename: Masaki
authors.initials: M
authors.lastname: Kitajima
mesh_terms: D000328:Adult; D000368:Aged; D000932:Antiemetics / Q000008:administration & dosage; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage*; D003907:Dexamethasone / Q000008:administration & dosage; D004155:Diphenhydramine / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000401:mortality; D017239:Paclitaxel / Q000008:administration & dosage*; D011899:Ranitidine / Q000008:administration & dosage; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000401:mortality; D016019:Survival Analysis
chemical_list: D000932:Antiemetics; D000972:Antineoplastic Agents, Phytogenic; D003907:Dexamethasone; D011899:Ranitidine; D004155:Diphenhydramine; D017239:Paclitaxel